Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Sagimet says license partner Ascletis will present positive full 52-week results from its Phase 3 open-label extension clinical trial of denifanstat in acne, along with mechanistic data, at the 2026 Fall Clinical Dermatology Conference.
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. NASDAQ:SGMT, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive 52-week results from the Phase 3 ASC40-304 OLE cli…
Sagimet Biosciences said 52-week results from Ascletis’ Phase 3 open-label extension of denifanstat in moderate to severe acne showed 56.7% IGA success, with sustained improvements and no adverse event-related permanent discontinuations reported.